Document Format Files
| Seq | Description | Document | Type | Size |
|---|---|---|---|---|
| 1 | F-1 | tm2415654-12_f1.htm | F-1 | 8004708 |
| 2 | EXHIBIT 3.1 | tm2415654d13_ex3-1.htm | EX-3.1 | 414521 |
| 3 | EXHIBIT 4.2 | tm2415654d13_ex4-2.htm | EX-4.2 | 1142 |
| 4 | EXHIBIT 10.1 | tm2415654d13_ex10-1.htm | EX-10.1 | 47996 |
| 5 | EXHIBIT 10.2 | tm2415654d13_ex10-2.htm | EX-10.2 | 99648 |
| 6 | EXHIBIT 10.3 | tm2415654d13_ex10-3.htm | EX-10.3 | 151193 |
| 7 | EXHIBIT 10.4 | tm2415654d13_ex10-4.htm | EX-10.4 | 111695 |
| 8 | EXHIBIT 10.5 | tm2415654d13_ex10-5.htm | EX-10.5 | 117504 |
| 9 | EXHIBIT 10.6 | tm2415654d13_ex10-6.htm | EX-10.6 | 115511 |
| 10 | EXHIBIT 10.7 | tm2415654d13_ex10-7.htm | EX-10.7 | 338999 |
| 11 | EXHIBIT 10.8 | tm2415654d13_ex10-8.htm | EX-10.8 | 197670 |
| 12 | EXHIBIT 10.9 | tm2415654d13_ex10-9.htm | EX-10.9 | 240926 |
| 13 | EXHIBIT 10.10 | tm2415654d13_ex10-10.htm | EX-10.10 | 16725 |
| 14 | EXHIBIT 10.11 | tm2415654d13_ex10-11.htm | EX-10.11 | 22825 |
| 15 | EXHIBIT 10.12 | tm2415654d13_ex10-12.htm | EX-10.12 | 89988 |
| 16 | EXHIBIT 10.13 | tm2415654d13_ex10-13.htm | EX-10.13 | 103933 |
| 17 | EXHIBIT 10.14 | tm2415654d13_ex10-14.htm | EX-10.14 | 493026 |
| 18 | EXHIBIT 10.15 | tm2415654d13_ex10-15.htm | EX-10.15 | 100896 |
| 19 | EXHIBIT 10.16 | tm2415654d13_ex10-16.htm | EX-10.16 | 129384 |
| 20 | EXHIBIT 10.17 | tm2415654d13_ex10-17.htm | EX-10.17 | 122037 |
| 21 | EXHIBIT 10.18 | tm2415654d13_ex10-18.htm | EX-10.18 | 21426 |
| 22 | EXHIBIT 10.19 | tm2415654d13_ex10-19.htm | EX-10.19 | 31975 |
| 23 | EXHIBIT 10.20 | tm2415654d13_ex10-20.htm | EX-10.20 | 144312 |
| 24 | EXHIBIT 21.1 | tm2415654d13_ex21-1.htm | EX-21.1 | 6920 |
| 25 | EXHIBIT 23.1 | tm2415654d13_ex23-1.htm | EX-23.1 | 1909 |
| 26 | EX-FILING FEES | tm2415654d13_ex-filingfees.htm | EX-FILING FEES | 25255 |
| 27 | GRAPHIC | bc_decreasing-4c.jpg | GRAPHIC | 42665 |
| 28 | GRAPHIC | bc_efficacyreports-4c.jpg | GRAPHIC | 58652 |
| 29 | GRAPHIC | bc_molecular-4clr.jpg | GRAPHIC | 30684 |
| 30 | GRAPHIC | bc_monotherapy-4c.jpg | GRAPHIC | 44428 |
| 31 | GRAPHIC | bc_response-4c.jpg | GRAPHIC | 58247 |
| 32 | GRAPHIC | bc_selectclinical-4c.jpg | GRAPHIC | 58026 |
| 33 | GRAPHIC | bc_synergistic-4clr.jpg | GRAPHIC | 136267 |
| 34 | GRAPHIC | bc_threemonths-4clr.jpg | GRAPHIC | 18698 |
| 35 | GRAPHIC | fc_candidates-4c.jpg | GRAPHIC | 31832 |
| 36 | GRAPHIC | fc_carcinoma-4c.jpg | GRAPHIC | 79032 |
| 37 | GRAPHIC | fc_cashflows-4c.jpg | GRAPHIC | 137590 |
| 38 | GRAPHIC | fc_compunds-4c.jpg | GRAPHIC | 67294 |
| 39 | GRAPHIC | fc_dialydose-4c.jpg | GRAPHIC | 41058 |
| 40 | GRAPHIC | fc_glora-4c.jpg | GRAPHIC | 51050 |
| 41 | GRAPHIC | fc_glora2-4c.jpg | GRAPHIC | 50245 |
| 42 | GRAPHIC | fc_glora3-4c.jpg | GRAPHIC | 55325 |
| 43 | GRAPHIC | fc_lisaftoclax-4c.jpg | GRAPHIC | 74410 |
| 44 | GRAPHIC | fc_lisareggrials-4c.jpg | GRAPHIC | 54142 |
| 45 | GRAPHIC | fc_olverembatinib-4c.jpg | GRAPHIC | 70059 |
| 46 | GRAPHIC | fc_polaris1-4c.jpg | GRAPHIC | 36116 |
| 47 | GRAPHIC | fc_polaris2-4clr.jpg | GRAPHIC | 75757 |
| 48 | GRAPHIC | fc_regtrials-4c.jpg | GRAPHIC | 32676 |
| 49 | GRAPHIC | fc_summary-4c.jpg | GRAPHIC | 85642 |
| 50 | GRAPHIC | lc_bestoverallres-4c.jpg | GRAPHIC | 101661 |
| 51 | GRAPHIC | lc_cumulative-4c.jpg | GRAPHIC | 58472 |
| 52 | GRAPHIC | lc_eventfreesurvival-4clr.jpg | GRAPHIC | 43902 |
| 53 | GRAPHIC | lc_median-4clr.jpg | GRAPHIC | 29321 |
| 54 | GRAPHIC | lc_patients-4clr.jpg | GRAPHIC | 33505 |
| 55 | GRAPHIC | lg_ascentagepharma-4clr.jpg | GRAPHIC | 26109 |
| 56 | GRAPHIC | ph_alrizomadlin-4clr.jpg | GRAPHIC | 121607 |
| 57 | GRAPHIC | ph_anemia-4clr.jpg | GRAPHIC | 73637 |
| 58 | GRAPHIC | ph_apoptosome-4clr.jpg | GRAPHIC | 67653 |
| 59 | GRAPHIC | ph_mechanism-4clr.jpg | GRAPHIC | 86748 |
| 60 | GRAPHIC | tb_44patiens-4c.jpg | GRAPHIC | 87495 |
| 61 | GRAPHIC | tb_amlpatients-4c.jpg | GRAPHIC | 53450 |
| 62 | GRAPHIC | tb_combination-4c.jpg | GRAPHIC | 34939 |
| 63 | GRAPHIC | tb_mutations-4c.jpg | GRAPHIC | 172150 |
| 64 | GRAPHIC | tb_safetyresults-4c.jpg | GRAPHIC | 73591 |
| 65 | GRAPHIC | tm15654d8_ex10-19img001.jpg | GRAPHIC | 8513 |
| 66 | GRAPHIC | tm2415654d8_ex10-10img001.jpg | GRAPHIC | 5061 |
| 67 | GRAPHIC | tm2415654d8_ex10-15img001.jpg | GRAPHIC | 9205 |
| 68 | GRAPHIC | tm2415654d8_ex10-17img001.jpg | GRAPHIC | 37782 |
| 69 | GRAPHIC | tm2415654d8_ex10-17img01.jpg | GRAPHIC | 6204 |
| 70 | GRAPHIC | tm2415654d8_ex10-18img001.jpg | GRAPHIC | 3648 |
| 71 | GRAPHIC | tm2415654d8_ex10-9img001.jpg | GRAPHIC | 5200 |
| 72 | GRAPHIC | tm2415654d8_ex3-1img004.jpg | GRAPHIC | 3269 |
| 73 | GRAPHIC | tm2415654d8_ex4-2img001.jpg | GRAPHIC | 132322 |
| 74 | GRAPHIC | tm242515654d11_ex10-20img001.jpg | GRAPHIC | 26344 |
| Complete submission text file | 0001104659-24-132177.txt | 14825943 |
EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: F-1 | Act: 33 | File No.: 333-284064 | Film No.: 241586171
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)
